<p>Mirum Pharmaceuticals, Inc.（纳斯达克代码：MIRM - 获取免费报告）在周六的午盘交易中创下了 52 周的新高，此前 Citizens Jmp 将该股的目标价从 95.00 美元上调至 140.00 美元。Citizens Jmp 目前对该股的评级为市场表现优于大盘。Mirum Pharmaceuticals 的股价最高达到 79.95 美元，最后交易价为 77.74 美元，成交量为 3828816 股。该股此前收盘价为 70.28 美元。</p>
<p>获取 <strong>Mirum Pharmaceuticals</strong> 的提醒：</p>
<p>其他一些分析师也最近对该股发表了评论。Evercore ISI 在 12 月 8 日的研究报告中将 Mirum Pharmaceuticals 的目标价从 89.00 美元上调至 94.00 美元，并给予公司 “表现优于大盘” 的评级。Wall Street Zen 在 9 月 26 日的研究报告中将 Mirum Pharmaceuticals 的评级从 “买入” 上调至 “强力买入”。JMP Securities 在 11 月 5 日的研究报告中对 Mirum Pharmaceuticals 设定了 95.00 美元的目标价。摩根大通在 9 月 12 日的研究报告中将 Mirum Pharmaceuticals 的目标价从 53.00 美元上调至 77.00 美元，并给予该股 “增持” 评级。最后，花旗集团在周五的报告中重申了对 Mirum Pharmaceuticals 的 “表现优于大盘” 评级。两位投资分析师给予该股 “强力买入” 评级，十二位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “买入”，共识目标价为 100.25 美元。</p>
<p><strong>获取我们关于 Mirum Pharmaceuticals 的最新报告</strong></p>
<h2>对 Mirum Pharmaceuticals 的对冲基金看法</h2>
<p>一些机构投资者最近调整了对该公司的持股。Tudor Investment Corp ET AL 在第三季度购买了价值约 202.7 万美元的 Mirum Pharmaceuticals 新股份。CIBC Bancorp USA Inc.在第三季度购买了价值约 31.5 万美元的 Mirum Pharmaceuticals 新股份。PharVision Advisers LLC 在第三季度购买了价值约 27.3 万美元的 Mirum Pharmaceuticals 新股份。Virtus Advisers LLC 在第三季度购买了价值约 29.3 万美元的 Mirum Pharmaceuticals 新股份。最后，Voleon Capital Management LP 在第三季度购买了价值 634.3 万美元的 Mirum Pharmaceuticals 新股份。</p>
<h2>Mirum Pharmaceuticals 上涨 10.6%</h2>
<p>该公司的 50 日简单移动平均线为 70.49 美元，200 日简单移动平均线为 64.45 美元。公司的速动比率为 3.16，流动比率为 3.31，债务与股本比率为 1.06。该股的市值为 40 亿美元，市盈率为-90.39，贝塔值为 0.42。</p>
<p>Mirum Pharmaceuticals（纳斯达克代码：MIRM - 获取免费报告）最后一次公布季度财报是在 11 月 4 日，报告显示该季度每股收益为 0.05 美元，超出市场共识预期的-0.10 美元 0.15 美元。该季度公司的收入为 1.3301 亿美元，而分析师预期为 1.3011 亿美元。Mirum Pharmaceuticals 的股本回报率为-16.47%，净利润率为-8.78%。该公司的季度收入较去年同期增长了 47.1%。在去年同期，该公司每股收益为-0.30 美元。股票分析师预测 Mirum Pharmaceuticals, Inc.在本年度将发布-1.43 美元的每股收益。</p>
<h2>关于 Mirum Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Mirum Pharmaceuticals, Inc 是一家处于后期阶段的生物制药公司，致力于开发和商业化针对罕见胆汁淤积性肝病的创新疗法。该公司的主要关注点是解决患有遗传性和进行性儿童肝病患者未满足的医疗需求，目前治疗选择有限。</p>
<p>Mirum 的主要产品候选药物 maralixibat（Livmarli）是一种肠道胆盐转运蛋白抑制剂，旨在减少全身胆盐的积累，并缓解相关的瘙痒和肝损伤。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Mirum Pharmaceuticals</li>
<li>电动车股票及其盈利方式</li>
<li>耐克财报超预期，但在中国市场面临挑战并遭遇关税</li>
<li>纽约证券交易所与纳斯达克的区别，以及这对投资者的重要性</li>
<li>人工智能热潮是泡沫吗？这两只分红股票表示不是</li>
<li>如何交易便士股票：逐步指南</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Mirum Pharmaceuticals 吗？</h2>
<p>在考虑 Mirum Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Mirum Pharmaceuticals 并不在名单上。</p>
<p>虽然 Mirum Pharmaceuticals 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

MIRM

<p>Mirum Pharmaceuticals（纳斯达克代码：MIRM）在 Citizens Jmp 将其目标价从 95 美元上调至 140 美元，并维持市场跑赢大盘评级后，达到了新的 52 周高点。该股交易最高达到 79.95 美元，收盘价为 77.74 美元，较 70.28 美元上涨。分析师对该股给予了一致的 “买入” 评级，目标价为 100.25 美元。机构投资者最近调整了他们的持股，该公司报告的季度每股收益为 0.05 美元，超出预期</p>

<p>Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) hit a new 52-week high during mid-day trading on Saturday after Citizens Jmp raised their price target on the stock from $95.00 to $140.00. Citizens Jmp currently has a market outperform rating on the stock. Mirum Pharmaceuticals traded as high as $79.95 and last traded at $77.74, with a volume of 3828816 shares traded. The stock had previously closed at $70.28.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals, Inc.（纳斯达克代码：MIRM - 获取免费报告）在周六的午盘交易中创下了 52 周的新高，此前 Citizens Jmp 将该股的目标价从 95.00 美元上调至 140.00 美元。Citizens Jmp 目前对该股的评级为市场表现优于大盘。Mirum Pharmaceuticals 的股价最高达到 79.95 美元，最后交易价为 77.74 美元，成交量为 3828816 股。该股此前收盘价为 70.28 美元。</p>
</div><p>Get <strong>Mirum Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Mirum Pharmaceuticals</strong> 的提醒：</p>
</div><p>A number of other analysts have also recently commented on the stock. Evercore ISI upped their price target on shares of Mirum Pharmaceuticals from $89.00 to $94.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, December 8th. Wall Street Zen raised Mirum Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Friday, September 26th. JMP Securities set a $95.00 target price on Mirum Pharmaceuticals in a research report on Wednesday, November 5th. JPMorgan Chase &amp; Co. raised their target price on Mirum Pharmaceuticals from $53.00 to $77.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, September 12th. Finally, Citigroup reiterated an &#34;outperform&#34; rating on shares of Mirum Pharmaceuticals in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Buy&#34; and a consensus target price of $100.25.</p>
<div class="lb-trans"><p>其他一些分析师也最近对该股发表了评论。Evercore ISI 在 12 月 8 日的研究报告中将 Mirum Pharmaceuticals 的目标价从 89.00 美元上调至 94.00 美元，并给予公司 “表现优于大盘” 的评级。Wall Street Zen 在 9 月 26 日的研究报告中将 Mirum Pharmaceuticals 的评级从 “买入” 上调至 “强力买入”。JMP Securities 在 11 月 5 日的研究报告中对 Mirum Pharmaceuticals 设定了 95.00 美元的目标价。摩根大通在 9 月 12 日的研究报告中将 Mirum Pharmaceuticals 的目标价从 53.00 美元上调至 77.00 美元，并给予该股 “增持” 评级。最后，花旗集团在周五的报告中重申了对 Mirum Pharmaceuticals 的 “表现优于大盘” 评级。两位投资分析师给予该股 “强力买入” 评级，十二位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “买入”，共识目标价为 100.25 美元。</p>
</div><p><strong>Get Our Latest Report on Mirum Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Mirum Pharmaceuticals 的最新报告</strong></p>
</div><h2>Hedge Funds Weigh In On Mirum Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Mirum Pharmaceuticals 的对冲基金看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of the company. Tudor Investment Corp ET AL bought a new position in shares of Mirum Pharmaceuticals in the third quarter valued at approximately $2,027,000. CIBC Bancorp USA Inc. bought a new position in Mirum Pharmaceuticals in the 3rd quarter worth approximately $315,000. PharVision Advisers LLC purchased a new position in Mirum Pharmaceuticals in the 3rd quarter valued at approximately $273,000. Virtus Advisers LLC purchased a new position in Mirum Pharmaceuticals in the 3rd quarter valued at approximately $293,000. Finally, Voleon Capital Management LP bought a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at $6,343,000.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对该公司的持股。Tudor Investment Corp ET AL 在第三季度购买了价值约 202.7 万美元的 Mirum Pharmaceuticals 新股份。CIBC Bancorp USA Inc.在第三季度购买了价值约 31.5 万美元的 Mirum Pharmaceuticals 新股份。PharVision Advisers LLC 在第三季度购买了价值约 27.3 万美元的 Mirum Pharmaceuticals 新股份。Virtus Advisers LLC 在第三季度购买了价值约 29.3 万美元的 Mirum Pharmaceuticals 新股份。最后，Voleon Capital Management LP 在第三季度购买了价值 634.3 万美元的 Mirum Pharmaceuticals 新股份。</p>
</div><h2>Mirum Pharmaceuticals Trading Up 10.6%</h2>
<div class="lb-trans"><h2>Mirum Pharmaceuticals 上涨 10.6%</h2>
</div><p>The firm has a 50-day simple moving average of $70.49 and a 200-day simple moving average of $64.45. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The stock has a market cap of $4.00 billion, a PE ratio of -90.39 and a beta of 0.42.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 70.49 美元，200 日简单移动平均线为 64.45 美元。公司的速动比率为 3.16，流动比率为 3.31，债务与股本比率为 1.06。该股的市值为 40 亿美元，市盈率为-90.39，贝塔值为 0.42。</p>
</div><p>Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to analysts' expectations of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm's quarterly revenue was up 47.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.30) earnings per share. Equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals（纳斯达克代码：MIRM - 获取免费报告）最后一次公布季度财报是在 11 月 4 日，报告显示该季度每股收益为 0.05 美元，超出市场共识预期的-0.10 美元 0.15 美元。该季度公司的收入为 1.3301 亿美元，而分析师预期为 1.3011 亿美元。Mirum Pharmaceuticals 的股本回报率为-16.47%，净利润率为-8.78%。该公司的季度收入较去年同期增长了 47.1%。在去年同期，该公司每股收益为-0.30 美元。股票分析师预测 Mirum Pharmaceuticals, Inc.在本年度将发布-1.43 美元的每股收益。</p>
</div><h2>About Mirum Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Mirum Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals, Inc 是一家处于后期阶段的生物制药公司，致力于开发和商业化针对罕见胆汁淤积性肝病的创新疗法。该公司的主要关注点是解决患有遗传性和进行性儿童肝病患者未满足的医疗需求，目前治疗选择有限。</p>
</div><p>Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.</p>
<div class="lb-trans"><p>Mirum 的主要产品候选药物 maralixibat（Livmarli）是一种肠道胆盐转运蛋白抑制剂，旨在减少全身胆盐的积累，并缓解相关的瘙痒和肝损伤。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Mirum Pharmaceuticals</li>
<li>EV Stocks and How to Profit from Them</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>How the NYSE and NASDAQ are Different, Why That Matters to Investors</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>How to trade penny stocks: A step-by-step guide</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Mirum Pharmaceuticals</li>
<li>电动车股票及其盈利方式</li>
<li>耐克财报超预期，但在中国市场面临挑战并遭遇关税</li>
<li>纽约证券交易所与纳斯达克的区别，以及这对投资者的重要性</li>
<li>人工智能热潮是泡沫吗？这两只分红股票表示不是</li>
<li>如何交易便士股票：逐步指南</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Mirum Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Mirum Pharmaceuticals 吗？</h2>
</div><p>Before you consider Mirum Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Mirum Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mirum Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Mirum Pharmaceuticals 并不在名单上。</p>
</div><p>While Mirum Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Mirum Pharmaceuticals 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Mirum Pharmaceuticals（NASDAQ:MIRM）在分析师上调评级后创下新的 52 周高点